secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001641172-25-008761
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Hepion in-licenses diagnostic tests from New Day Diagnostics for $0.725M upfront
--------------------------------------------------------------------------------

- In-licensed celiac, respiratory multiplex (COVID/flu A/B/RSV), H. pylori, and HCC tests; three have CE marks for EU sale.
- Upfront consideration: $525k cash + $200k in unregistered common stock to New Day Diagnostics.
- Milestone payments up to $17.15M on regulatory, sales, and reimbursement milestones; royalties in upper single to low double digits.
- Binding LOI is effective immediately; termination requires mutual consent. Parties to execute definitive license agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000164117225008761/0001641172-25-008761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000164117225008761/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-008761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer